Table 2.
Up-regulated | ||||
---|---|---|---|---|
Age/Tumor status | Method | Probe Hits | Unique Genes | Overlap |
2 months/Early in tumorigenesis | CAM | 46 | 40 | |
Partek (p ≤ 0.05) | 19 | 18 | 11 | |
Partek (p ≤ 0.01) | 7 | 7 | 4 | |
12 months/Established tumors | CAM | 296 | 260 | |
Partek (p ≤ 0.05) | 303 | 283 | 71 | |
Partek (p ≤ 0.01) | 64 | 63 | 16 | |
Down-regulated | ||||
Age/Tumor status | Method | Probe Hits | Unique Genes | Overlap |
2 months/Early in tumorigenesis | CAM | 86 | 73 | |
Partek (p ≤ 0.05) | 18 | 18 | 10 | |
Partek (p ≤ 0.01) | 7 | 7 | 5 | |
12 months/Established tumors | CAM | 246 | 165 | |
Partek (p ≤ 0.05) | 470 | 432 | 46 | |
Partek (p ≤ 0.01) | 92 | 89 | 13 |
The number of differentially expressed probes hits and corresponding unique genes identified by a parametric (Partek) approach or nonparametric (CAM) approach are shown The overlap of genes identified by both approaches is also shown for p ≤ 0.05 or ≤ 0.01.